Syed Kazmi, M.D.: Internal Medicine ...

Dr. Syed M. Kazmi

Claim this profile

UT Southwestern/Simmons Cancer Center-Dallas

Studies Colon Cancer
Studies Colorectal Cancer
17 reported clinical trials
33 drugs studied

Area of expertise

1Colon Cancer
Syed M. Kazmi has run 10 trials for Colon Cancer. Some of their research focus areas include:
Stage IV
Stage III
BRAF negative
2Colorectal Cancer
Syed M. Kazmi has run 8 trials for Colorectal Cancer. Some of their research focus areas include:
Stage IV
Stage III
MLH1 positive

Affiliated Hospitals

Image of trial facility.
UT Southwestern/Simmons Cancer Center-Dallas
Image of trial facility.
Parkland Memorial Hospital

Clinical Trials Syed M. Kazmi is currently running

Image of trial facility.

Circulating Tumor DNA

for Colorectal Cancer

This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.
Recruiting1 award N/A6 criteria
Image of trial facility.

Ceralasertib + Trastuzumab Deruxtecan

for Solid Tumors

The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change (mutation) in the HER2 gene or protein and have spread to other places in the body (advanced). The dose expansion phase (phase Ib) of this trial compares how colorectal and gastroesophageal cancers with HER2 mutation respond to treatment with a combination of ceralasertib and trastuzumab deruxtecan versus trastuzumab deruxtecan alone. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers deruxtecan to kill them. Ceralasertib and trastuzumab deruxtecan may be safe, tolerable and effective in treating patients with advanced solid tumors expressing the HER2 protein or gene.
Recruiting1 award Phase 126 criteria

More about Syed M. Kazmi

Clinical Trial Related8 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Syed M. Kazmi has experience with
  • Atezolizumab
  • Nivolumab
  • Cetuximab
  • Bevacizumab
  • Oxaliplatin
  • Fluorouracil

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Syed M. Kazmi specialize in?
Is Syed M. Kazmi currently recruiting for clinical trials?
Are there any treatments that Syed M. Kazmi has studied deeply?
What is the best way to schedule an appointment with Syed M. Kazmi?
What is the office address of Syed M. Kazmi?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security